Schwarmdynamik und soziales Miteinander. Zur 'improvisierten Choreographie' You've Changed von Thomas Hauert und der Kompanie ZOO

Der Aufsatz beschäftigt sich mit der 'improvisierten Choreographie' You've Changed des Schweizer Choreographen Thomas Hauert und seiner in Brüssel angesiedelten Kompanie ZOO. Mittels der Denkfigur des Schwarms werden die Funktions- und Organisationsprinzipien der schwärmenden Konstellationen, welche die Tanzenden immer wieder bilden, beschrieben und analysiert. Zusätzlich werden die kinästhetischen Übertragungsprozesse erläutert, die sich in dieser Live-Improvisation zwischen den Tanzenden ereignen. Mittels Überlegungen, die der französische Philosoph Jean-Luc Nancy in seiner Schrift singulär plural sein entwickelt hat, wird anschließend diskutiert, wie in dieser 'improvisierten Choerographie' das gemeinsame Sein beständig ausgehandelt wird, wobei eine heterogene und zugleich integrierte Gemeinschaft entsteht.

"Die Schweiz sollte eine aktivere Rolle spielen" (Interview mit Thomas Cottier von Andreas Valda)

Thomas Cottier, Experte für Handelsrecht, erklärt, warum die Pharmaindustrie beim Freihandelsabkommen mit Indien zu viel verlangt. Und warum die Schweiz bei internationalen Handelskonflikten mehr unternehmen müsste.

Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus

Transcatheter (or percutaneous) renal denervation is a novel technique developed for the treatment of resistant hypertension. So far, only one randomised controlled trial has been published, which has shown a reduction of office blood pressure. The Swiss Society of Hypertension, the Swiss Society of Cardiology, The Swiss Society of Angiology and the Swiss Society of Interventional Radiology decided to establish recommendations to practicing physicians and specialists for good clinical practice. The eligibility of patients for transcatheter renal denervation needs (1.) confirmation of truly resistant hypertension, (2.) exclusion of secondary forms of hypertension, (3.) a multidisciplinary decision confirming the eligibility, (4.) facilities that guarantee procedural safety and (5.) a long-term follow-up of the patients, if possible in cooperation with a hypertension specialist. These steps are essential until long-term data on safety and efficacy are available.

Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial

Background Biodegradable polymers for release of antiproliferative drugs from metallic drug-eluting stents (DES) aim to improve long-term vascular healing and efficacy. We designed a large scale clinical trial to compare a novel thin strut, cobalt chromium DES with silicon carbide coating releasing sirolimus from a biodegradable polymer (Orsiro, O-SES) with the durable polymer-based Xience Prime everolimus-eluting stent (X-EES) in an all-comers patient population. Design The multicenter BIOSCIENCE trial (NCT01443104) randomly assigned 2,119 patients to treatment with biodegradable polymer SES or durable polymer EES at 9 sites in Switzerland. Patients with chronic stable coronary artery disease or acute coronary syndromes, including non-ST-elevation and ST-elevation myocardial infarction, were eligible for the trial if they had at least one lesion with a diameter stenosis >50% appropriate for coronary stent implantation. The primary endpoint target lesion failure (TLF) is a composite of cardiac death, target-vessel myocardial infarction, and clinically-driven target lesion revascularization within 12 months. Assuming a TLF rate of 8% at 12 months in both treatment arms and accepting 3.5% as a margin for non-inferiority, inclusion of 2,060 patients would provide 80% power to detect non-inferiority of the biodegradable polymer SES compared with the durable polymer EES at a one-sided type I error of 0.05. Clinical follow-up will be continued through five years. Conclusion The BIOSCIENCE trial will determine whether the biodegradable polymer SES is non-inferior to the durable polymer EES with respect to TLF.